BAY 58–2667, a soluble guanylate cyclase activator, improves cardiopulmonary haemodynamics in acute decompensated heart failure and has a favourable safety profile by Harald Lapp et al.
BioMed CentralBMC Pharmacology
ssOpen AcceOral presentation
BAY 58–2667, a soluble guanylate cyclase activator, improves 
cardiopulmonary haemodynamics in acute decompensated heart 
failure and has a favourable safety profile
Harald Lapp*1, Veselin Mitrovic2, Norbert Franz3, Hubertus Heuer4, 
Michael Buerke5, Judith Wolfertz6, Wolfgang Mück7, Sigrun Unger8, 
Georg Wensing7 and Reiner Frey7
Address: 1HELIOS-Klinikum Erfurt, 99089 Erfurt, Germany, 2Kerckhoff-Klinik Nauheim, 61231 Nauheim, Germany, 3Schüchtermann-Klinik Bad 
Rothenfelde, 49214 Bad Rothenfelde, Germany, 4St Johannes Hospital Dortmund,44137 Dortmund, Germany, 5Universität Halle, 06097 Halle, 
Germany, 6HELIOS-Klinikum Wuppertal, 42283 Wuppertal, Germany, 7Clinical Pharmacology, Bayer HealthCare AG, Pharma Research Centre, 
42096 Wuppertal, Germany and 8Global Biostatistics, Bayer HealthCare AG, Pharma Research Centre, 42096 Wuppertal, Germany
Email: Harald Lapp* - harald.lapp@helios-kliniken.de
* Corresponding author    
Background
BAY 58–2667 is a soluble guanylate cyclase (sGC) activa-
tor that acts independently of nitric oxide (NO) and
haem. Data from preclinical studies show that BAY 58–
2667 preferentially dilates diseased vessels, without the
development of tolerance [1]. In healthy humans, this
novel agent has a favourable safety profile and is well tol-
erated. We hypothesized that BAY 58–2667 would
improve cardiopulmonary haemodynamics and be well
tolerated in patients with acute decompensated heart fail-
ure (ADHF).
Materials and methods
This was a non-randomized, uncontrolled, unblinded,
multicentre phase II study in patients with ADHF (pulmo-
nary capillary wedge pressure [PCWP] ≥ 18 mmHg). After
initial dose-finding studies (part A) using 50, 100, 200
and 400 μg/h, respectively, BAY 58–2667 was evaluated
(part B) using a starting dose of 100 μg/h, which could be
titrated after 2 h, 4 h and 6 h to doses between 50 μg/h
and 400 μg/h, depending on the haemodynamic
response. Haemodynamic parameters were measured by
pulmonary artery catheter and impedance cardiography.
Patients were categorized as responders if their PCWP
decreased by ≥4 mmHg compared with baseline. Thirty-
three patients were eligible for the safety evaluation and
30 for the haemodynamic evaluations (part B).
Results
Haemodynamic parameters at baseline were: PCWP, 25
mmHg; right atrial pressure (RAP), 13 mmHg; mean pul-
monary artery pressure (PAPmean), 36 mmHg; systolic
blood pressure (SBP), 119 mmHg; systemic vascular
resistance (SVR), 1581 dyn·s·cm-5; heart rate (HR), 76.7
beats per minute (bpm); and cardiac index, 2.1 L/min/
m2. Final doses of BAY 58–2667 after 6 h of infusion
were: 50 μg/h (n = 2); 200 μg/h (n = 12); and 400 μg/h (n
= 16). Compared with baseline, a 6 h infusion of BAY 58–
2667 reduced PCWP by 7.9 mmHg, RAP by 2.9 mmHg,
PAPmean by 6.5 mmHg, SBP by 13.9 mmHg and SVR by
597 dyn·s·cm-5, while increasing HR by 4.4 bpm and car-
diac index by 0.82 L/min/m2. The responder rate was 53%
after 2 h, 83% after 4 h and 90% after 6 h. BAY 58–2667
was well tolerated. Of the 33 patients, six individuals
reported 11 adverse events (AEs) of mild-to-moderate
intensity and there was one serious AE. Three AEs were
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related to the study drug (hypotension and sickness) and
eight were not. There was no evidence of tachyphylaxis.
Conclusion
These first clinical results with BAY 58–2667 in patients
with ADHF demonstrate the potential of this new thera-
peutic principle. In patients with ADHF, continuous
parenteral administration of BAY 58–2667 was well toler-
ated and induced potent arterial and venous vasodilation,
which resulted in significant reductions in cardiac pre-
and after-load and an increase in cardiac index. These data
also suggest that a pool of oxidized or haem-free sGC is
present in human ADHF; these forms are preferentially
activated by BAY 58–2667.
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